Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies completes REVEAL pivotal dosing and reports longer-term TSHA-102 data

Positive Impact 4 of 5 other Written later

Taysha Gene Therapies said it has completed dosing of 17 patients in its REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term data from the Part A trials. The company said the data show gains in developmental milestones at 12 months and beyond, with no treatment-related serious adverse events reported, but the results are company-reported, come from small patient groups, and do not yet include an FDA decision on a BLA submission.

Key points

  • Dosing completed for 17 patients in the REVEAL pivotal trial; topline data from the 6-month interim analysis and FDA feedback expected in the first half of 2027.
  • 100% of 12 REVEAL Part A patients gained or regained at least one developmental milestone by 12 months after treatment.
  • 310 functional gains were observed at 12 months or more after treatment (about 26 per patient), including 31 developmental milestones.
  • No treatment-related serious adverse events or dose-limiting toxicities reported as of the June 2026 data cutoff (N=29).

The filing

CompanyTaysha Gene Therapies, Inc. (TSHA)
Form8-K, current report
Filed with the SECJun 22, 2026, 8:14 AM ET
Accession number0001193125-26-276738

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.